Section of Rheumatology, Department of Pediatrics, University of Colorado School of Medicine, 13123 East 16th Avenue B-311, Aurora, CO 80045, USA.
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, 9500 Euclid Avenue A50, Cleveland, OH 44195, USA.
Rheum Dis Clin North Am. 2023 Aug;49(3):563-584. doi: 10.1016/j.rdc.2023.03.006.
Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis that affects a variety of organ systems. Historically, glucocorticoids and a variety of other immunosuppressants were used to abrogate the inflammation and tissue injury associated with EGPA. The management of EGPA has evolved greatly during the last decade with the development of novel targeted therapeutics that have resulted in significantly improved outcomes for these patients, with many more novel targeted therapies emerging.
嗜酸性肉芽肿性多血管炎（EGPA）是一种嗜酸性粒细胞血管炎，可影响多种器官系统。历史上，糖皮质激素和多种其他免疫抑制剂被用于消除与 EGPA 相关的炎症和组织损伤。在过去十年中，随着新型靶向治疗药物的发展，EGPA 的治疗有了很大的发展，这些患者的预后得到了显著改善，并且出现了更多的新型靶向治疗药物。
